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Exudative age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness
worldwide. Many recent genetic association studies on large caseecontrol cohorts have helped in
drawing an outline of the pathogenesis of AMD. The majority of the associations observed in oxidative
stress and lipid peroxidation (complement factor H or CFH), complement (CFH, C3, complement factor I, C2,
complement factor B), and neovascularization (vascular endothelial growth factor A, high-temperature
requirement factor A1) genes have been replicated in diverse populations worldwide. In this review,
we have provided an overview on the genetic factors in the pathogenesis of AMD, and highlight their
underlying molecular genetic mechanisms. Further comprehensive research is needed to verify this
outline, to explore the treatment target, and to develop the effective primary and secondary prevention
of AMD.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
1.1. Age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of
visual impairment in elderly individuals and is the most common
cause of blindness in Western countries.1,2 Advanced AMD has two
major subtypes, namely, geographic atrophy (also called advanced
“dry” AMD) and choroidal neovascularization (CNV; also called
exudative AMD or “wet” AMD). Exudative AMD affects 10e15% of
patients with AMD and rapidly progresses to blindness if left
untreated.3
1.2. Hypothesis of AMD pathogenesis
In the early stages of AMD, the abnormal oxidative stress in
retinal pigment epithelium (RPE) triggers the dysfunction or
changes in the composition or permeability of Bruch’s membrane,ial ﬁnancial and nonﬁnancial
gy, Peking University People’s
eng District, Beijing 100044,
ciety of Taiwan. Published by Elseleading to the formation of drusen. Drusen are small, yellowish
extracellular deposits of cellular debris, protein, lipid, carbohydrate,
complement components, and anaphylatoxins. Local inﬂammatory
and immune-mediated events play an important role in the devel-
opment of drusen.4e8 In turn, the inﬂammation becomes chronic
and increasingly ampliﬁed over decades as the outer macula be-
comes even more hypoxic. The complement system may play a
central role in chronic inﬂammation. The inﬂammation triggers the
production of vascular endothelial growth factor (VEGF), whichwas
identiﬁed to play a major role in CNV in 1996.9,10 A previous study
demonstrated that VEGF plays a role in the progression of CNV and
enhancement of vascular permeability, both of which result in loss
of vision.11 It stimulates dissociation of tight junction components,
promotes vascular permeability, and endothelial cell growth.12,13 In
the late stages of AMD, there is excessive recruitment of scar tissue
that leads to irreversible destruction of photoreceptors (Fig. 1).
2. Role of genetic factors in the pathogenesis of AMD
Recent large-sample genome-wide association studies (GWASs)
conﬁrmed previously reported AMD-associated genes, including
complement factor H (CFH),14 high-temperature requirement factor A1
(HTRA1),14 age-related maculopathy susceptibility protein 2
(ARMS2),14 C3,14,15 VEGFA,14 etc. In this paper, the role of these genes
in the pathogenesis of AMD is reviewed.vier Taiwan LLC. All rights reserved.
Fig. 1. Hypothesis of age-related macular degeneration pathogenesis. APOE ¼ apolipoprotein E; ARMS2 ¼ age-related maculopathy susceptibility protein 2; CFB ¼ complement
factor B; CFH ¼ complement factor H; CFI ¼ complement factor I; HTRA1 ¼ high-temperature requirement factor A1; VEGFA ¼ vascular endothelial growth factor A.
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stage
Increased oxidative stress has been implicated in the patho-
genesis of AMD.16,17 Owing to oxidative stress, proteins, lipids, and
DNA can be damaged. When phospholipids in cell membranes
undergo lipid peroxidation, malondialdehyde (MDA) and other
reactive decomposition products are generated.18 Previous studies
have reported that oxidative stress and lipid peroxidation-related
genesdCFH and apolipoprotein E (APOE)dare associated with AMD.
2.1.1. CFH protects from oxidative stress
The CFH is one of the ﬁrst genes reported to be associated with
AMD.19 Individualswith a CFH variant that substitutes a tyrosine for a
histidine at position 402 have an increased likelihood of developing
AMD by 4.6-folds if the variation is present on one allele and by 7.4-
folds if it is present on both alleles.19 Further CFH studies found that
the CFH haplotype signiﬁcantly increased the risk for AMDwith odds
ratios (ORs) between 2.45 and 5.57 and that a common variant likely
explains approximately 43% of AMD in older adults.20e25
Recent research found that CFH is an innate defense protein
against oxidative stress.17 Results from animal models lacking im-
munoglobulins showed that over 55% of peptides that bind to MDA
could be attributed to CFH. Mapping of the binding site for MDA on
CFH showed that it crossed the amino acid position 402, high-
lighted in the original genetic association studies and, most
importantly, the H402 variant of CFH showed reducedMDA binding
by up to 23% in the plasma of heterozygotes and up to 52% in ho-
mozygotes. Normal CFH then appears to protect against inﬂam-
mation by inhibiting the complement pathway; however, once
mutated, the CFH’s ability to control the inﬂammation associated
with AMD appears to be lost. Functioning CFH is able to suppress
the inﬂammatory response by mopping up the MDA adducts.17
2.1.2. APOE suppresses lipid peroxidation
APOE is a lipid transport protein that acts as a ligand for the low-
density lipoprotein (LDL) receptor, which is involved in the main-
tenance and repair of neuronal cell membranes. Variation at two
single-nucleotide polymorphisms (SNPs) within the coding
sequence of the APOE gene, rs429358 and rs7412, results in different
isoforms reported to attenuate binding afﬁnity to the LDL receptor.
Three allelic variants derived from these SNPs commonly referred to
as ε2, ε3, and ε4 are differentiated based on cysteine (Cys) andarginine (Arg) residue interchanges at positions 112 (rs429358) and
158 (rs7412) in the amino acid. APOε2 has a much reduced binding
afﬁnity leading to lower total cholesterol levels with respect to
APOε3andAPOε4,which reveal a higher binding afﬁnitywithhigher
total cholesterol levels.26 The APOE has been found to be associated
with AMD. A pooled analysis of 15 studies demonstrated the asso-
ciations between late AMD and APOε4 (OR ¼ 0.72 per haplotype)
and APOε2 (OR ¼ 1.83 for homozygote carriers).27
APOE plays an important role in suppressing the oxidative stress
and lipid peroxidation. APOE binds directly to 4-hydroxynonenal
and has a protective effect against lipid peroxidation.28 A recent
study found that lipid peroxidation is caused by a reduction of
antioxidant activity with aging in APOE knockout mice.29
2.1.3. Role of genetic factors in chronic inﬂammation
Oxidatively modiﬁed proteins are known to induce inﬂamma-
tory responses and are recognized by innate immunity.30,31 The
oxidation-speciﬁc epitopes are recognized as danger signals by
innate immune receptors.32 Following a series of independent
research papers in late 2005 suggesting a link between the body’s
immune system and AMD, further investigations established the
alternative complement system as a potentially critical player that
may help scientists to join the dots between drusen, a fatty tissue
characteristic of the disease, and the symptomatic degeneration of
the macula. Understanding the links between the genetic suscep-
tibility data and the clinical symptoms should provide a framework
for a deeper understanding of AMD pathogenesis and consequently
contribute to identifying new therapeutic targets to slow or halt
vision loss associated with the disease.
2.1.4. CFH
We have previously discussed that CFH protects from oxidative
stress. Moreover, CFH plays an important role in the regulation of
the alternative pathway. CFH binds C3b, and accelerates the decay
of the alternative C3 convertase (C3bBb). It also acts as a cofactor for
the inactivation of C3b by complement factor I (CFI).33,34 CFH binds
to cell surfaces to regulate ampliﬁcation of the alternative com-
plement pathway resulting from spontaneous C3b deposition,
which occurs on any surface in contact with blood.33,34
2.1.5. Complement C3
Complement C3 is the most abundant component of the comple-
ment pathway. Variations in the C3 gene are associated with AMD. A
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with AMD.35e37 Another C3 variant (rs1047286) is also associated
with AMD.20,36 Furthermore, some rare variants, such as p.Arg1210-
Cys38 and p.Pro314Leu,15 are associated with a high risk of AMD.
C3 may have an important role in the pathogenesis of AMD. C3
messenger RNA can be detected in the neural retina, choroids, and
RPE.7 Local C3a levels increase in the experimental model of wet
AMD.39 Eliminating the C3 gene protects from CNV development
after exposure to laser in C3 gene knockout mice.40 Furthermore,
C3a may increase VEGF secretion40 and recruitment of monocytes
by intercellular adhesion molecule 1 production.
2.1.6. CFI
CFI is a serine protease that cleaves and inactivates C4b and C3b.
A C>T transition (rs10033900) located downstream from the 30-
untranslated region of the CFI gene has been shown to be associ-
ated with AMD.41,42 Recently, some rare variants in CFI, such as
p.Gly119Arg43 and p.Pro50Ala,44 are associated with a high risk of
advanced AMD.
The effect of CFI variations on AMD formation may be due to a
reduction in the degradation of C3b. A recent study found that
plasma and sera from cases carrying the p.Gly119Arg substitution
mediated the degradation of C3b to a lesser extent than those from
controls.43
2.1.7. Complement C2/complement factor B
Complement component 2 (C2) and complement factor B (CFB) are
described together because of similarities in structure, function,
and genetic characteristics.34 The C2 gene, located on 6p21.33, en-
codes a serum glycoprotein that functions as part of the classical
complement pathway, which is involved in innate immunity and
inﬂammation.45 Two polymorphisms, rs9332739 G > C and
rs547154 G > T, have been implicated in AMD. The C2 poly-
morphisms may be associated directly with AMD or indirectly
through the high level of linkage disequilibrium that exists be-
tween C2 and CFB, which is located downstream on the same
chromosome.20,46,47
The protective effect of C2/CFB variations may due to a reduction
in formation of either classical or alternative pathway C3 con-
vertase. Montes et al48 found that the CFB 32Q variant had up to
four times less C3b binding afﬁnity than the nonrisk 32R protein,
with consequent reduction in C3 convertase formation.
2.2. Role of genetic factors in neovascularization
2.2.1. VEGF
VEGF is a signal protein produced by cells and stimulates vas-
culogenesis and angiogenesis. VEGFA is the most important mem-
ber of the VEGF family. VEGFA plays a particularly important role in
the pathogenesis of wet AMD. Anti-VEGF therapies are the ﬁrst-line
treatment for AMD.49e51 Previous studies found that VEGF poly-
morphisms are associated with neovascular AMD.
Previous studies on VEGF and AMD have yielded conﬂicting re-
sults. Some caseecontrol studies reported signiﬁcant associations for
VEGF polymorphisms,52e54 but the validity of these results remains
unconﬁrmed.55 A recent collaborative GWAS, including 17,100
advanced AMD cases and 60,000 controls, found that the rs943080
variant in VEGFA is associated with increased risk of AMD.14
2.2.2. High-temperature requirement factor A1 and ARMS2
Numerous genetic association studies have shown that chro-
mosome 10q26 is a major candidate region associated with the
susceptibility of AMD.56 The linkage peak was reﬁned to two
neighboring genes, HTRA157e59 and ARMS2.20,60,61HTRA1 is a multifunctional serine protease. Overexpression of
human HTRA1 in mouse eyes leads to CNV and polypoidal choroidal
vasculopathy in mice.62 Further studies found that HTRA1 regulates
angiogenesis through transforming growth factor-b family member
growth differentiation factor 6.63
The function of ARMS2 has not yet been clearly demonstrated.
Polymorphisms in ARMS2 and HTRA1 are strongly associated with
AMD, whereas the strong linkage disequilibrium in the genomic
region makes their effects indistinguishable in statistical analyses.
Some experiments showed that ARMS2 localizes to the mitochon-
drial outer membrane.60 Other studies claimed that ARMS2 is
mainly distributed in the cytosol.64
3. Conclusion
The growing genetic evidence draws an outline of the patho-
genesis of AMD. Further comprehensive research is needed to
verify this outline, to explore the treatment target, and to develop
the effective primary and secondary prevention of AMD.
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